Home > Insider Trading > Filing (0001144204-17-059447)

Filing Details

Accession Number:: 0001144204-17-059447
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-15 16:35:52
Reporting Period:: 2017-11-13

Accepted Time:: 2017-11-15 16:35:52
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631574	Wave Life Sciences Ltd.	WVE	()	MA

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1346824	Ra Capital Management, Llc	20 Park Plaza, Suite 1200 Boston MA 02116		Yes	No	Yes	No
1384859	Peter Kolchinsky	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Acquisiton	2017-11-13	400,000	$23.30	7,488,651	No	4	P	Indirect	See Footnote
Ordinary Shares	Acquisiton	2017-11-14	23,398	$24.00	7,512,049	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

These securities are held in a separately managed account (the "Account").
RA Capital Management, LLC (the "Adviser") is the general partner of RA Capital Healthcare Fund, L.P. (the "Fund") and the investment adviser of the Account. Peter Kolchinsky is a director of the issuer and is the sole manager of the Adviser. In their respective capacities, each of Mr. Kolchinsky and the Adviser may be deemed to beneficially own the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934.
The Adviser and Mr. Kolchinsky disclaim beneficial ownership of the reported securities for purposes of Rule 16a-1(a)(1) under the Exchange Act in reliance on Rule 16a-1(a)(1)(v) and (vii), respectively. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Mr. Kolchinsky is or was, for purposes of Rule 16a-1(a)(1) under the Exchange Act, the beneficial owner of any of the securities reported herein. Mr. Kolchinsky and the Adviser disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a)(2) under the Exchange Act except to the extent of their pecuniary interest therein.
The prices reported in Column 4 are weighted average prices. The shares were purchased in multiple transactions at prices ranging from $23.78 to $23.70, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Following the reported transactions, the Fund held 6,582,428 shares and the Account held 929,621 shares.